Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination therapy consisting of methylphenidate, a central nervous system stimulant primarily used to treat attention-deficit/hyperactivity disorder (ADHD), and vitamin D, a fat-soluble secosteroid involved in calcium homeostasis and bone metabolism. Methylphenidate acts as a norepinephrine–dopamine reuptake inhibitor, increasing the synaptic concentrations of these neurotransmitters in the brain to improve attention and reduce hyperactivity[5]. Vitamin D supplementation has been studied as an adjunctive therapy with methylphenidate for ADHD; evidence suggests it may provide additional improvement in ADHD symptoms, particularly evening symptoms, without significant adverse effects[1][3]. The combination is not available as a fixed-dose pharmaceutical product but refers to concurrent use of both agents.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methylphenidate + vitamin D.